Human Papillomavirus Archives - Infectious Disease Advisor

The HPV vaccine protects against the human papillomaviruess and causes most cervical cancers. It is recommended for male and female patients aged 11 to 12 years. Stressing the importance of the vaccine to boys, especially, can help reduce spread of the disease. The vaccine can be administered to female patients aged 26 and under and male patients aged 21 years and younger.

Rates of New HPV Detection and Loss of Detection in Middle-Age Women

By

September 22, 2020

Researchers conducted a prospective cohort study to assess rates of new HPV detection and loss of detection in middle-age women.

The approval is based on evidence that the vaccine can prevent anogenital infections, with an ongoing trial looking at throat infection prevention in men likely to be critical for continued approval.

Genitourinary

Gardasil 9 for the Prevention of Some Head and Neck Cancers: Measuring the Benefit

By

Victoria Forster, PhD

August 13, 2020

The approval is based on evidence that the vaccine can prevent anogenital infections, with an ongoing trial looking at throat infection prevention in men likely to be critical for continued approval.

Sexually Transmitted Diseases

HPV Prevalence Higher in Adults With More Than 5 Lifetime Sexual Partners

By

Sweta Gupta

August 12, 2020

Clinicians must consider patient sexual history in the decision-making process for adult HPV vaccination.

Shedding Light on the Importance of HPV Vaccination

Genitourinary

Teen HPV Vaccination Rates Suboptimal

August 5, 2020

Lack of parental intent to initiate and complete the human papillomavirus (HPV) vaccine series for adolescents is a major public health concern.

Respiratory

DNA-Based Therapy Gets Orphan Drug Status for Recurrent Respiratory Papillomatosis

By

Brian Park, PharmD

August 4, 2020

The FDA has granted Orphan Drug designation to INO-3107, a DNA plasmid immunotherapy, for the treatment of recurrent respiratory papillomatosis, a rare disease caused by human papillomavirus types 6 and 11 infections.

Genitourinary

Gardasil 9 Approved to Prevent Certain HPV-Related Head and Neck Cancers

By

Brian Park, PharmD

June 17, 2020

The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.

Genitourinary

HPV Vaccine Toolkit Increases Vaccination Rates in Primary Care

By

Madeline Morr

June 12, 2020

The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.

Prevention

Bivalent HPV Vaccine Induces Robust Serologic Response Nine Years Postvaccination

By

Infectious Disease Advisor Contributing Writer

February 4, 2020

In addition to high antibody levels, factors including exposure to the human papillomavirus (HPV) and antibody avidity may be important and necessary to protect against infection.

Prevention

Mortality Risk Among Patients With Oropharynx Cancer Varies Based on HPV Status

January 16, 2020

For patients with oropharynx cancer, the rates of head and neck cancer mortality and competing mortality vary depending on HPV status.

Prevention

CDC Reports Increasing Rate of Adults Who Received HPV Vaccine

January 9, 2020

From 2013 to 2018, there was an increase in the percentage of adults aged 18 to 26 years who received one or more doses or the recommended number of doses of HPV vaccine.